Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1
|
作者：
Escudier, Bernard [1 ]
Joly, Florence [2 ]
Soria, Jean-Charles [3 ]
机构：
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Ctr Francois Baclesse, F-14076 Caen 05, France
[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2011年 / 98卷
关键词：
renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;
D O I：
10.1684/bdc.2011.1444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta
引用
收藏
页码：S3 / S6
页数：4
相关论文
共 50 条
  • [31] Renal Cancer Stem Cells: Characterization and Targeted Therapies
    Peired, Anna Julie
    Sisti, Alessandro
    Romagnani, Paola
    STEM CELLS INTERNATIONAL, 2016, 2016
  • [32] Systemic therapy and novel targeted therapies in renal cancer
    Gore, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 12 - 12
  • [33] GENOMICS IN TRANSLATIONAL RESEARCH AND TARGETED THERAPIES IN RENAL CANCER
    Jhanwar, Suresh C.
    ANTICANCER RESEARCH, 2014, 34 (10) : 5978 - 5979
  • [34] Renal cancer: signaling pathways and advances in targeted therapies
    Jiang, Aimin
    Li, Jinxin
    He, Ziwei
    Liu, Ying
    Qiao, Kun
    Fang, Yu
    Qu, Le
    Luo, Peng
    Lin, Anqi
    Wang, Linhui
    MEDCOMM, 2024, 5 (08):
  • [35] Management of side-effects of targeted therapies in renal cancer: gastrointestinal side-effects
    Davin, Jean-Louis
    Ducrotte, Philippe
    Houede, Nadine
    BULLETIN DU CANCER, 2011, 98 : S69 - S78
  • [36] Management of side effects of targeted therapies in renal cancer: stomatological side effects (mucositis, epistaxis)
    Agbo-Godeau, Scarlette
    Nicolas-Virelizier, Emmanuelle
    Scotte, Florian
    BULLETIN DU CANCER, 2011, 98 : S117 - S126
  • [37] Biological therapies in breast cancer: Common toxicities and management strategies
    Barroso-Sousa, Romualdo
    Santana, Iuri A.
    Testa, Laura
    Gagliato, Debora de Melo
    Mano, Max S.
    BREAST, 2013, 22 (06): : 1009 - 1018
  • [38] Management of side-effects of targeted therapies in renal cancer: cardiovascular side-effects
    Ederhy, Stephane
    Duclos, Brigitte
    Mahammedi, Hakim
    Doublet, Jean-Dominique
    BULLETIN DU CANCER, 2011, 98 : S19 - S34
  • [39] Oral targeted therapies in non-small cell cancer - managing toxicities
    Alexander, Marliese
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 55 - 55
  • [40] Pulmonary toxicities from targeted therapies: a review
    Nicholas A. Barber
    Apar Kishor Ganti
    Targeted Oncology, 2011, 6 : 235 - 243
12345